FiftyBidsGovernment contracts and grants, sent to your inbox.

Back to search

Open grant

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM).

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesRefer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.)
How muchup to $700K per award; about 4 awards; $4.4 million total
DeadlineMon, Jan 11, 2027 (80 days left)
CategoryHealth
TypeCooperative agreement
Opportunity #RFA-CA-27-005
Assistance listing93.394, 93.395
PostedMon, Aug 31, 2026

Open the official posting

From the notice

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.